President & CEO, NFlection Therapeutics
William Hodder joined NFlection in October 2021 as Chief Executive Officer, bringing more than 35 years of broad biopharmaceutical industry experience including fundraising, business development, corporate and product marketing, sales, and product development. Most recently, Mr. Hodder was Chief Business Officer for Escient Pharmaceuticals a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs for neuro-immuno-inflammatory and autoreactive diseases. Previously, he was Senior Vice President, Corporate Development at Protagonist Therapeutics (Nasdaq: PTGX). Prior to joining Protagonist, Mr. Hodder was a co-founder and CEO of Trenovus, Inc., and. previously served as Vice President of Business Development and Corporate Officer at FibroGen, Inc. Prior to joining FibroGen, Mr. Hodder served as Director of Business Development and Marketing at Aradigm, and has also held sales, marketing, and product development positions at Penederm (acquired by Mylan Laboratories), Ciba Geigy (now Novartis), Bristol-Myers Squibb Company, and Marion Laboratories (now Sanofi). Mr. Hodder received a B.S. in biology from Oakland University and an M.B.A. from The University of Chicago Booth School of Business.